Magnitude of late asthmatic response to allergen in relation to baseline and allergen-induced sputum eosinophilia in mild asthmatic patients.
BACKGROUND
Late asthmatic response (LAR) to allergen challenge is a validated method for studying the pathogenesis of and new treatments for asthma in the laboratory.


OBJECTIVE
To evaluate the relationship between the magnitude of allergen-induced LAR and clinical and biological determinants, including sputum and blood eosinophil percentages and eosinophil cationic protein concentrations.


METHODS
Thirty-eight untreated mild asthmatic patients (mean age, 21.2 years) were selected for the presence of allergen-induced early asthmatic response (EAR) and LAR. Each patient measured methacholine responsiveness (provocation dose that caused a decrease in forced expiratory volume in 1 second of 20% [PD20FEV1]) at baseline, differential blood cell counts and eosinophil cationic protein levels in blood and induced sputum, and serum neutrophil chemotactic activity at baseline and 24 hours after allergen challenge.


RESULTS
A correlation was found between LAR (as area under the curve [AUC]) and sputum eosinophil percentages at baseline (r = 0.51; P = .001) and 24 hours after allergen challenge (r = 0.44; P < .007). Furthermore, we found significant correlations between AUC LAR and AUC EAR, baseline methacholine PD20FEV1, baseline blood eosinophil percentages, and baseline serum neutrophil chemotactic activity. A stepwise multiple regression analysis showed that the stronger determinants of AUC LAR were baseline sputum eosinophilia and AUC EAR.


CONCLUSIONS
Baseline sputum eosinophilia and functional findings are determinants of the magnitude of allergen-induced LAR.
Dente
Federico L
FL
Cardio-Thoracic Department, Respiratory Pathophysiology, University Hospital of Pisa, Pisa, Italy. med013@dcap.med.unipi.it
Bacci
Elena
E
Bartoli
Maria Laura
ML
Cianchetti
Silvana
S
Di Franco
Antonella
A
Costa
Francesco
F
Vagaggini
Barbara
B
Paggiaro
Pier Luigi
PL
D000293:Adolescent; D000328:Adult; D000485:Allergens / Q000008:administration & dosage / Q000276:immunology; D001249:Asthma / Q000097:blood / Q000276:immunology* / Q000503:physiopathology; D001985:Bronchial Provocation Tests / Q000379:methods*; D002452:Cell Count; D002634:Chemotaxis, Leukocyte / Q000276:immunology; D047150:Eosinophil Cationic Protein / Q000097:blood / Q000378:metabolism; D004802:Eosinophilia / Q000097:blood / Q000276:immunology*; D004804:Eosinophils / Q000166:cytology; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007958:Leukocyte Count; D016676:Macrophages, Alveolar / Q000166:cytology; D008297:Male; D016210:Methacholine Chloride / Q000494:pharmacology; D009504:Neutrophils / Q000166:cytology; D013183:Sputum / Q000166:cytology* / Q000276:immunology / Q000378:metabolism
D000485:Allergens; D016210:Methacholine Chloride; D047150:Eosinophil Cationic Protein; C479220:RNASE3 protein, human